GALMED PHARMACEUTICALS LTD. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
GALMED PHARMACEUTICALS LTD. (GLMD) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $3.04 million as of 2026-06-30, per its 6-K filed 2026-09-02.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-09-02
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $3.04M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $4.11M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $3.44M.
- 2025-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $5.09M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations |
|---|---|
| 2026-06-30 | $3.04M 6-K · filed 2026-09-02 |
| 2025-12-31 | $4.11M 6-K · filed 2026-09-02 |
| 2025-09-30 | $3.44M 6-K · filed 2025-11-26 |
| 2025-06-30 | $5.09M 6-K · filed 2026-09-02 |
| 2024-12-31 | $4.77M 6-K · filed 2026-09-02 |
| 2024-09-30 | $8.68M 6-K · filed 2025-11-26 |
| 2024-06-30 | $1.96M 6-K · filed 2025-08-28 |
| 2023-12-31 | $2.98M 20-F · filed 2026-03-31 |
| 2023-06-30 | $1.12M 6-K · filed 2024-08-28 |
| 2022-12-31 | $2.13M 20-F · filed 2026-03-31 |
| 2022-06-30 | $2.09M 6-K · filed 2023-08-09 |
| 2021-12-31 | $3.00M 20-F · filed 2025-04-02 |
| 2021-06-30 | $8.04M 6-K · filed 2022-08-04 |
| 2020-12-31 | $7.06M 20-F · filed 2024-04-04 |
| 2020-06-30 | $5.67M 6-K · filed 2021-08-05 |
| 2019-12-31 | $16.04M 20-F · filed 2023-03-29 |
| 2018-12-31 | $24.16M 20-F · filed 2022-05-02 |